PURPOSE OF THE STUDY: The purpose of the study is to learn if an investigational medication (AZD7325) helps to improve social communication in adults with high-functioning autism. Investigational drugs are medications that have not been approved by the Food and Drug Administration (FDA) to be sold in the US. This study drug has not been approved by the FDA to treat Autism Spectrum Disorder, however the drug is designed to target the GABA neurotransmitter system, a chemical system found widely distributed in the brain and which is believed to be abnormal in people with ASD. We will also assess if people with autism perform differently on measures of brain activity than people without autism. This study will hopefully help with future medication research for people with autism spectrum disorder.
PARTICIPANTS AND STUDY DESIGN: Eligible participants must have been diagnosed with an autism spectrum disorder (ASD). The study is sponsored by the National Institute of Mental Health and will last for up to 13 weeks. Adults ages 18-35 will be included in this national study, and approximately 10 from UCLA
CONTACT US: If you are interested in learning more about this research study, please contact UCLA study coordinator Jenny Cowen, Ph.D. at (310) 825-6170 or email UCLAadhd.email@example.com.
Originally created: 10 Jan 2014 Current author: System Admin
Jane & Terry Semel Institute for Neuroscience & Human Behavior
760 Westwood Plaza
Los Angeles, CA 90095
UCLA Health System School of Medicine
(c) UC Regents 2011 Privacy Notice
Help Sitemap A-Z index